Challenging T-ALL to IL-7Rp dual inhibition. Read more about Challenging T-ALL to IL-7Rp dual inhibition.
How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Read more about How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Read more about Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering.
NFIA-ETO2, TP53, and erythroid leukemogenesis. Read more about NFIA-ETO2, TP53, and erythroid leukemogenesis.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Read more about Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. Read more about Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Read more about North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Read more about Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. Read more about KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
Engineering builds multipotency for iPSC-NKs. Read more about Engineering builds multipotency for iPSC-NKs.
